Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/jcm10071390
Keywords
psoriasis; COVID-19; SARS-CoV-2; systemic therapy; biologics
Categories
Ask authors/readers for more resources
Psoriasis is a chronic inflammatory disease that mainly affects the skin and joints, but recent therapeutic advancements, particularly biologics, have significantly improved treatment outcomes. During the COVID-19 pandemic, the use of biologics for psoriasis treatment appears to have some benefits against COVID-19 infection, emphasizing the importance of shared decision-making based on updated information.
Psoriasis is a chronic, immune-mediated inflammatory disease that predominantly affects the skin and joints. The recent therapeutic development for psoriasis has been remarkable and biologics have dramatically changed the treatment of psoriasis. In moderate-to-severe cases, systemic therapies are required to control their symptoms and biologics can provide greater efficacy when compared with other types of therapies. The coronavirus disease (COVID-19) pandemic has had a great impact on the lives of many people and has worsened substantially worldwide. During the ongoing COVID-19 pandemic, it still remains unclear whether biologics suppress the immune system and increase the risk of COVID-19. In this review, we have summarized the experience with biologics used for treating psoriasis during the COVID-19 pandemic. Biologics seem to be beneficial to COVID-19 infection. Shared decision-making that is based on updated information is highlighted in the time of COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available